Mumbai, February 27, 2025: Global pharma major Lupin Limited (Lupin) proudly announces its inclusion in prestigious S&P Global Sustainability Yearbook 2025, for the second consecutive year. This recognition highlights Lupin’s exceptional performance and dedication to sustainability. Lupin has been included in the Top 10% S&P Global CSA Score – which refers to companies that rank within the top 10% of their industry, based on their Corporate Sustainability Assessment (CSA) Score for 2024.

Yearbook members are selected basis their S&P Global 2024 Corporate Sustainability Assessment (CSA) score. Lupin’s S&P Global CSA score has significantly improved, from 65 to 75, in 2024. This year, 7,690 companies assessed in the 2024 CSA were considered for the 2025 Sustainability Yearbook, out of which only 780 companies across 62 industries were recognized.

Commenting on the achievement, Ramesh Swaminathan, Executive Director, Global CFO and Head – API Plus SBU, Lupin said, “Being featured in the S&P Global Sustainability Yearbook for the second consecutive year underscores our unwavering commitment to sustainability. We are at the forefront of the pharmaceutical industry in promoting sustainable business practices globally. We remain committed to advancing impactful initiatives that support a sustainable and equitable future for our patients, communities, and stakeholders worldwide.”

Reference: https://www.spglobal.com/esg/csa/yearbook/2025/ranking/index

About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin

For further information or queries, please contact:

Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com